Business
Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium
(NewsDirect) Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Lo...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals \"sees a gap in the market\" for domestically-produced barium\n \n \n (NewsDirect)\n \n \n \n \n Proactive Research Analyst Daniel Appiah\nspeaks to Thomas Warner from the Londons studio after publishing a new\nresearch note on Canadian medical imaging contrast media company\nVoyageur Pharmaceuticals Ltd (TSX-V:VM) (OTC:VYYRF).\n \n \n Appiah gives an overview of the note and\nthe company itself, explaining that contrast agents containing barium\nsulphate or iodine are consumed prior to x-rays or CT scans, aiding\ndoctors in visualizing the interior of the body.\n \n \n Voyageur aims to leverage its own\nfacilities and resources to establish an integrated value chain for\nthese agents in North America. The company has already launched its\nfirst product in Canada, with plans to expand to the US post-FDA\napprovals.\n \n \n By 2025, Voyageur intends to source barium from its\nfully-owned Frances Creek Mine, potentially reducing raw ingredient\ncosts significantly. Appiah explains that Voyageur is currently\nseeking funding to help support its development.\n \n \n \n Contact\nDetails\n \n \n \n Proactive Investors\n \n \n +1 604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":1684,"tagName":"div"}]